Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287482 · ClinicalTrials.gov registry record · NA
Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.
A NA study, sponsored by Women and Infants Hospital of Rhode Island.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00287482 is a NA study that was terminated before completion, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 20 participants.
The verdict
NCT00287482, a NA study, was terminated before completion, sponsored by Women and Infants Hospital of Rhode Island.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a pilot feasibility study being performed in women completing front-line treatment for breast or ovarian cancer. It is being done to evaluate whether or not an herbal combination known as Essiac (ESIAK) can improve the overall quality of life in these women as they transition from active treatment to follow-up, also known as the quality of life in transition. This information will be used to design a larger randomized trial.
Interventions
- DRUG Essiac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287482
The ClinicalTrials.gov registry entry for NCT00287482 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Women and Infants Hospital of Rhode Island, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Essiac is the first listed.
NCT00287482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287482 about?
NCT00287482 is a clinical study titled "Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.". This is a pilot feasibility study being performed in women completing front-line treatment for breast or ovarian cancer. It is being done to evaluate whether or not an herbal combination known as Essiac (ESIAK) can improve the overall quality of life in these women as they transition from active tre...
What is the current status of trial NCT00287482?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2005-10. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00287482?
The interventions under investigation include: Essiac (DRUG).
Who is sponsoring clinical trial NCT00287482?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.